Cambridge, MA, October 8, 2021 — Clínica Imbanaco, a leading research organization in Colombia, has joined the TriNetX network to maximize its research capacity and to expand its collaboration with other research sites around the world. Headquartered in Cali, Colombia, Clínica Imbanaco’s Research Institute has participated in 143 industry-sponsored clinical trials since its founding in 2010.
“It is strategically important to become a member of the TriNetX global health research network,” said Dr. Martín Cañón, Head of the Research Institute at Clínica Imbanaco. “TriNetX provides a gateway to global real-world data and a community of peer institutions and industry sponsors who seek to collaborate in the generation of real-world evidence that will inform the development of new therapies, seeking better outcomes for the patients in our care.”
“Joining TriNetX aligns with our objectives to foster innovation and strengthen our educational and research programs at Clínica Imbanaco,” said Dr. Alejandro De La Torre, Scientific Director at Clínica Imbanaco. “In 2020, our researchers published 81 papers in scientific journals, and we now have nearly 50 clinical studies underway. We are excited to welcome new collaborative research opportunities with peers on the TriNetX network.”
Clínica Imbanaco, a part of the QuirónSalud group in Spain, has nine sites in Colombia with 351 beds. They have an outpatient center, an ambulatory facility with multiple therapeutic areas, a genomic medicine unit, ICUs, radiotherapy oncology, bone marrow transplants and a diagnostic center complete with a clinical analysis laboratory and a diagnostic imaging and pathology department.
“The TriNetX network will help magnify the visibility of Clínica Imbanaco as a leading clinical trial site in Colombia, as well as strengthen our institutional culture of research and innovation through collaboration with other research sites,” said Dr. Cañón.
TriNetX is the largest and fastest growing collaborative research network representing healthcare organizations and health data partners across the world. TriNetX has presented thousands of clinical trial opportunities to the healthcare organizations on its network and has been cited in hundreds of scientific and peer-reviewed publications.
“Clínica Imbanaco is a prestigious addition to the TriNetX network, and we are thrilled to welcome them as one of our newest members among the rapid expansion of the network in Latin America,” said Steve Lethbridge, Senior Vice President, Global Healthcare Partnerships at TriNetX. “We look forward to being a part of Clínica Imbanaco’s journey to increase international research collaboration.”
About Clínica Imbanaco
Clínica Imbanaco was founded in 1976 in Cali, Colombia. They are a private institution and since 2019 are part of the QuirónSalud group in Spain that has 53 hospitals (seven in LATAM). Within their clinic they have nine different sites covering all services including an outpatient center, an ambulatory facility with different therapeutic areas, a genomic medicine unit, 351 hospital beds, intensive care units (adults and children), radiotherapy oncology, bone marrow transplants, diagnostic center complete with clinical analysis Laboratory, diagnostic imaging and pathology. Clínica Imbanaco has an Research Institute which has a focus in different clinical specialties such as oncology, infectiology, cardiology, pediatrics, ophthalmology and orthopedics, among others. In the institutional research area, different studies have been carried out that have been socialized in different national and international events, as well as in indexed journals. For more information, visit https://www.imbanaco.com.
About TriNetX, LLC
TriNetX is a global network of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. Through its self-service, HIPAA, GDPR, and LGPD-compliant platform of federated EHR, datasets, and consulting partnerships, TriNetX puts the power of real-world data into the hands of its worldwide community to improve protocol design, streamline trial operations, and enrich real-world evidence generation. For more information, visit TriNetX at www.trinetx.com or follow @TriNetX on Twitter.
57 602 382 1000 Ext. 41254